|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CUTTING EDGE |

,




,¶
* Department of Internal Medicine,
Program in Immunology,
Department of Pathology and Immunology,
Department of Cell Biology, and
¶ Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Allergic airway inflammation is a Th2-mediated immune response in the lung. Following a single allergen challenge, sensitized mice develop an eosinophilic inflammatory cell infiltrate around airways and blood vessels, which spontaneously resolves (8). Although CD28 and ICOS mediate the initiation and maintenance of airway inflammation, the basis for resolution has not been fully explored (9, 10, 11, 12). In this study, we examined the role of BTLA and PD-1 in acute allergic airway inflammation by analysis of mice deficient in these inhibitory receptors. Although there was a minor role for these in regulating the intensity of acute airway inflammation, the receptors were crucial in limiting the duration of inflammation. This result correlated with the relatively late induction of the ligand for BTLA, herpes virus entry mediator (HVEM), and enhanced expression of the ligands for PD-1 at later times. These results suggest that the inhibitory receptors BTLA and PD-1 act as terminators of an established immune response, and may be important for limiting the extent and duration of inflammation at peripheral sites.
| Materials and Methods |
|---|
|
|
|---|
BTLA-deficient mice (strain Btlatm1kmm) in the C57BL/6 background were generated as described previously (3). PD-1-deficient mice (strain Pdcd1tm1hon) in the C57BL6/J background were obtained from Tasuka Honjo (Kyoto University, Kyoto, Japan). C57BL/6 mice were purchased from The Jackson Laboratory. All mice were housed in specific pathogen-free facilities at Washington University School of Medicine (St. Louis, MO). All animal studies have been approved by the Washington University Animal Studies Committee.
Antibodies
Anti-BTLA Ab (Clone 6F7, mouse IgG1) was generated as described previously (13). Anti-PD-1 and anti-CD4 Abs were purchased from eBioscience. Flow cytometric analysis was performed on a FACSCalibur cytometer using CellQuest software (BD Biosciences). Analysis was performed using FlowJo software.
Muc5AC staining
For Mucin 5AC immunostaining, Ag retrieval was performed using Ag Unmasking solution (Vector Laboratories). Lung sections were blocked with 2% fish gel in PBS and then incubated with biotinylated anti-mucin 5AC mAb (Neomarkers) at a final concentration of 2 µg/ml. Ab binding was visualized with Vectastain ABC Elite kit (Vector Laboratories), diaminobenzidine substrate, and hematoxylin counterstain.
RT-PCR and RNase protection assay (RPA)
Total RNA was extracted from lung tissue of control or allergen-challenged mice using TRIzol (Invitrogen Life Technologies). Random primed cDNA was prepared using the Retroscript kit (Ambion). Specific primers for PDL1, PDL2, and HVEM were designed that spanned intronic sequences. Control primers amplify ribosomal S15 RNA and are provided with the Retroscript kit. Multiprobe RPA was performed on total lung RNA using the mCK-1 probe set per the manufacturers directions (BD Pharmingen).
Experimental allergic airway inflammation
Mice were sensitized and challenged with OVA as described previously (11). Briefly, mice received injections i.p. with OVA adsorbed to alum on days 0 and 7. On day 14, they received an intranasal challenge of 50 µl of 2% OVA in the morning and afternoon. Samples were collected as previously described on the indicated days following inhaled challenge (11).
Preparation of murine tracheal epithelial cells (mTEC)
Primary mouse airway epithelial cells were cultured and differentiated using an established model of the mouse airway (14, 15). Briefly, epithelial cells were harvested from mouse tracheas of C57BL/6 mice (5- to 6-wk-old) using pronase digestion and differential adherence to yield a preparation composed of >99% epithelial cells. Mouse tracheal epithelial cells were cultured in the presence of growth factor-supplemented medium on semipermeable membranes (Transwell; Corning-Costar) and then cultured at air-liquid interface to generate a multilayer model of the airway composed of ciliated, secretory, and basal airway epithelial cells. RNA was prepared from day 7 ALI cultures using TRIzol reagent.
| Results and Discussion |
|---|
|
|
|---|
We first determined the kinetics of lymphocyte accumulation and receptor expression in vivo by examining the cells recovered in the bronchoalveolar lavage (BAL) fluid at days 1, 3, 4, or 7 following challenge. CD4+ T cells appeared in the BAL by day 3 and peaked on day 7 (Fig. 1). Staining for PD-1 and BTLA revealed that PD-1 expression gradually increased, being detectible on day 3 and reaching its maximum on day 7 following challenge. BTLA expression exhibited a reciprocal pattern with expression being greatest on day 3 and nearly undetectable by day 7 (Fig. 1).
|
|
We next examined the kinetics of expression of the ligands for each receptor. HVEM, the ligand for BTLA, was nearly undetectable in the first 4 days, but became detectable by day 7 and was maximal by day 10 and 15 (Fig. 3, upper panels). PDL1 expression was detectable early and increased over time, reaching a maximum between days 10 and 15 postchallenge. Expression of PD-L2, a second ligand for PD-1, was maximal at day 4 following intranasal challenge, and declined subsequently (Fig. 3). Both HVEM and PDL1 were detectable in RNA samples obtained from cultured mTEC, suggesting that the source of ligand may be nonimmune cells of the lung (Fig. 3, lane 8).
|
Given the observed kinetics of ligand expression, we next examined the allergic response at day 10 and day 15 following intranasal challenge (Fig. 4). Wild-type mice completely resolved the inflammation by day 10, as evidenced by a low number of cells recovered in the BAL fluid and histology (Fig. 4A). By contrast, mice deficient in BTLA and PD-1 showed a persistent increase in BAL cells on day 10 following intranasal challenge. Furthermore, the composition of these cells in this fluid revealed a greater proportion of lymphocytes and eosinophils in comparison to the few cells in the wild-type mice, which consisted predominantly of macrophages (Fig. 4A). Even on day 15, examination of BTLA-deficient mice revealed the continued presence of increased numbers of lymphocytes and eosinophils. Direct histological examination of H&E-stained sections also demonstrated persistent inflammation and mucus cell metaplasia in the lungs of both PD-1 and BTLA-deficient mice at days 10 and 15, whereas the wild-type mice had complete resolution in this time frame (Fig. 4B). Thus, these inhibitory receptors are critical for resolving airway inflammation.
|
-IFN in all mice with no difference between strains (data not shown). Overall, cytokine mRNA levels were decreased on days 10 and 15; however, there was a persistence of mRNA for IL-10 and
-IFN in the PD-1-deficient mice (Fig. 4C and data not shown). Of the four BTLA-deficient mice, one demonstrated persistence of cytokine message, whereas none of the wild-type mice had detectable message. Similar results were seen in samples collected on day 10 following challenge (data not shown). As we have previously observed, IL-15 was detected in all samples including unchallenged mice (Ref.10 and data not shown). T cell-dependent immune responses are determined by the integration of signals derived from both cell:cell interactions and soluble mediators. We have recently described a novel role for CD28 signaling not only in the early priming phase, but also in maintenance of the effector phase of allergic airway inflammation (11). These studies focused on an acute model, acting between days 1 and 3. By contrast, the present results show that the inhibitory receptors BTLA and PD-1 exert only a slight effect in attenuating the degree of acute inflammation but instead exert a profound effect on the duration of inflammation, suggesting they act to terminate the immune response. We also observed a temporal regulation of expression of the ligands for these receptors during the course of the inflammatory response. The differences in the kinetics of receptor and ligand expression for PD-1 and BTLA suggest that they may act at different times in the immune response. Alternatively, it remains possible that signaling through one regulates the expression or function of the other. Nonetheless, these data support that the regulated expression of inhibitory receptors on lymphocytes and their ligands in the lung are critical for the proper termination of the acute inflammatory response. We propose, based on these findings, that abnormalities in this immune axis could play a role in pathologic situations such as chronic persistent asthma and may represent novel targets for therapeutic intervention.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported in part by Grant HL062683 (to J.M.G.) from the National Institutes of Health. ![]()
2 Address correspondence and reprint requests to Dr. Jonathan M. Green, Washington University School of Medicine, 660 South Euclid Avenue, Box 8052, St. Louis, MO 63110. E-mail address: jgreen{at}im.wustl.edu ![]()
3 Abbreviations used in this paper: BTLA, B and T lymphocyte attenuator; PD-1, programmed death receptor-1; HVEM, herpes virus entry mediator; RPA, RNase protection assay; mTEC, murine tracheal epithelial cell; BAL, bronchoalveolar lavage. ![]()
Received for publication November 30, 2005. Accepted for publication January 27, 2006.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Tao, L. Wang, K. M. Murphy, C. C. Fraser, and W. W. Hancock Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells J. Immunol., May 15, 2008; 180(10): 6649 - 6655. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Nelson, M. D. Fremont, J. R. Sedy, P. S. Norris, C. F. Ware, K. M. Murphy, and D. H. Fremont Structural Determinants of Herpesvirus Entry Mediator Recognition by Murine B and T Lymphocyte Attenuator J. Immunol., January 15, 2008; 180(2): 940 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takamura, S. Fukuyama, T. Nagatake, D.-Y. Kim, A. Kawamura, H. Kawauchi, and H. Kiyono Regulatory Role of Lymphoid Chemokine CCL19 and CCL21 in the Control of Allergic Rhinitis J. Immunol., November 1, 2007; 179(9): 5897 - 5906. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lepenies, K. Pfeffer, M. A. Hurchla, T. L. Murphy, K. M. Murphy, J. Oetzel, B. Fleischer, and T. Jacobs Ligation of B and T Lymphocyte Attenuator Prevents the Genesis of Experimental Cerebral Malaria J. Immunol., September 15, 2007; 179(6): 4093 - 4100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Hurchla, J. R. Sedy, and K. M. Murphy Unexpected Role of B and T Lymphocyte Attenuator in Sustaining Cell Survival during Chronic Allostimulation J. Immunol., May 15, 2007; 178(10): 6073 - 6082. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |